Kim Ryungsa, Kin Takanori, Beck William T
Department of Breast Surgery, Hiroshima Mark Clinic, 1-4-3F, 2-Chome Ohte-machi, Naka-ku, Hiroshima 730-0051, Japan.
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Cancers (Basel). 2024 Feb 28;16(5):984. doi: 10.3390/cancers16050984.
Anticancer drugs induce apoptotic and non-apoptotic cell death in various cancer types. The signaling pathways for anticancer drug-induced apoptotic cell death have been shown to differ between drug-sensitive and drug-resistant cells. In atypical multidrug-resistant leukemia cells, the /activator protein 1 (AP-1)/ signaling pathway leading to apoptotic death is altered. Cancer cells treated with anticancer drugs undergo /AP-1-mediated apoptotic death and are involved in N-terminal kinase activation and growth arrest- and DNA damage-inducible gene 153 ()/CCAAT/enhancer-binding protein homologous protein pathway induction, regardless of the genotype. induction is associated with mitochondrial membrane permeabilization after anticancer drug treatment and involves a coupled endoplasmic reticulum stress response. The induction of apoptosis by anticancer drugs is mediated by the intrinsic pathway (cytochrome c, Cyt c) and subsequent activation of the caspase cascade via proapoptotic genes (e.g., and ) and their interactions. Anticancer drug-induced apoptosis involves caspase-dependent and caspase-independent pathways and occurs via intrinsic and extrinsic pathways. The targeting of antiapoptotic genes such as enhances anticancer drug efficacy. The modulation of apoptotic signaling by transduction increases the sensitivity of multidrug resistance-related protein-overexpressing epidermoid carcinoma cells to anticancer drugs. The significance of autophagy in cancer therapy remains to be elucidated. In this review, we summarize current knowledge of cancer cell death-related signaling pathways and their alterations during anticancer drug treatment and discuss potential strategies to enhance treatment efficacy.
抗癌药物可在多种癌症类型中诱导凋亡性和非凋亡性细胞死亡。已表明,抗癌药物诱导凋亡性细胞死亡的信号通路在药物敏感细胞和耐药细胞之间存在差异。在非典型多药耐药白血病细胞中,导致凋亡死亡的激活蛋白1(AP-1)信号通路发生改变。无论基因型如何,用抗癌药物处理的癌细胞都会经历AP-1介导的凋亡死亡,并参与N端激酶激活以及生长停滞和DNA损伤诱导基因153()/CCAAT增强子结合蛋白同源蛋白通路的诱导。诱导与抗癌药物处理后的线粒体膜通透性增加有关,并涉及内质网应激反应的耦合。抗癌药物诱导的凋亡由内在途径(细胞色素c,Cyt c)介导,随后通过促凋亡基因(例如和)及其相互作用激活半胱天冬酶级联反应。抗癌药物诱导的凋亡涉及半胱天冬酶依赖性和半胱天冬酶非依赖性途径,并通过内在和外在途径发生。靶向抗凋亡基因如可增强抗癌药物的疗效。通过转导调节凋亡信号可增加多药耐药相关蛋白过表达的表皮样癌细胞对抗癌药物的敏感性。自噬在癌症治疗中的意义仍有待阐明。在本综述中,我们总结了目前关于癌细胞死亡相关信号通路及其在抗癌药物治疗过程中改变的知识,并讨论了提高治疗效果的潜在策略。